Phuturdex › Diseases › Rheumatic Diseases
Drugs in development · updated 30 October 2026
Rheumatic Diseases: drugs in development
As of 30 October 2026 there are 4 active clinical trials (recruiting or ongoing, phases I–III) on 30 drugs for rheumatic Diseases. 3 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| SPY002-072 | II | 1 | NCT07148414 |
| IN026 | I | 1 | NCT07587684 |
| KN5601 | Early I | 1 | NCT07490041 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AbataceptOrencia® | II | 1 | NCT07138898 |
| AdalimumabHadlima, Simlandi® | II | 1 | NCT07138898 |
| AnakinraKINERET | II | 1 | NCT07138898 |
| AzathioprineImuran, Jayempi® | II | 1 | NCT07138898 |
| BelimumabBenlysta® | II | 1 | NCT07138898 |
| BimekizumabBimzelx® | II | 1 | NCT07138898 |
| CanakinumabIlaris®, Canakinumab Novartis® | II | 1 | NCT07138898 |
| Certolizumab | II | 1 | NCT07138898 |
| CyclosporineCyclosporine A, Cyclosporin Capsules | II | 1 | NCT07138898 |
| EtanerceptEticovo®, Erelzi® | II | 1 | NCT07138898 |
| GolimumabImmgolis®, Immgolis Intri® | II | 1 | NCT07138898 |
| GuselkumabTremfya | II | 1 | NCT07138898 |
| HydroxychloroquineSovuna®, Plaquenil® | II | 1 | NCT07138898 |
| InfliximabZymfentra®, Avsola® | II | 1 | NCT07138898 |
| IxekizumabTaltz® | II | 1 | NCT07138898 |
Sorted by most advanced phase and number of active trials. Showing 15 of 27 drugs.
All 30 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Rheumatoid arthritis 130 drugs
- Knee osteoarthritis 37 drugs
- Systemic lupus erythematosus 178 drugs
- Sjogren's Syndrome 29 drugs
- Arthritis, Juvenile 39 drugs
- Osteoarthritis 20 drugs
- Systemic scleroderma 77 drugs
- Autoimmune disease 94 drugs
- Myositis 42 drugs
- Gout 13 drugs
- Hyperuricemia 13 drugs
- Inflammation 85 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Joint Diseases 6 drugs
- Musculoskeletal disorder 22 drugs
- Connective tissue disease 21 drugs
- Immune System Diseases 54 drugs
- Autoimmune disease 94 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D012216 “Rheumatic Diseases”.